By Michael Erman NEW YORK, April 27 (Reuters) - Johnson & Johnson is using artificial intelligence to slash by half the time ...

For the first time, FDA regulators will be able to see what’s happening in a clinical trial, looking at endpoints in the ...

The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal ...

The tech giant’s new AI platform aims to make drug discovery faster and cleaner.

The company was aiming for approval in the second half of 2028, paving the way for a market launch in 2029 Hangzhou-based biotech start-up MindRank has progressed to Phase 3 clinical trials for its ...

Wanted: a cheap, multipotent treatment for viral infections. Must be able to handle new or unfamiliar strains, or (even ...

The US Food and Drug Administration (FDA) on Monday announced it will pilot a new program it hopes will spur the development of novel drug development tools (DDTs) that do not fit within the agency’s ...

Artificial intelligence and machine learning are being embedded in every aspect of the drug discovery and development process. In the preclinical stages, for example, companies are using advanced AI ...

A new procedural document issued by the US Food and Drug Administration (FDA) instructs its staff on the best practices-known as Good Review Practices (GVPs)-used in the review of investigational new ...

Twelve months after releasing a roadmap to shift away from animal testing requirements, the FDA has declared mission ...